Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future
Brian Godman*, Michael Wilcock, Andrew Martin, Scott Bryson, Christoph Baumgärtel, Tomasz Bochenek, Winne de Bruyn, Ljiljana Sovic Brkicic, Marco D'Agata, Antra Fogele, Anna Coma Fusté, Jessica Fraeyman, Jurij Fürst, Kristina Garuoliene, Harald Herholz, Mikael Hoffmann, Sisira Jayathissa, Hye Young Kwon, Irene Langner, Marija KalabaEva Andersén Karlsson, Ott Laius, Vanda Markovic-Pekovic, Einar Magnusson, Stuart McTaggart, Scott Metcalfe, Hanne Bak Pedersen, Jutta Piessnegger, Anne Marthe Ringerud, Gisbert W. Selke, Catherine Sermet, Krijn Schiffers, Peter Skiold, Juraj Slabỳ, Dominik Tomek, Anita Viksna, Agnes Vitry, Corinne Zara, Rickard E. Malmström
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
11Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future'. Together they form a unique fingerprint.